- MVD and primary PCI: which strategy?
- 'The Great Debate' - Dual antiplatelet therapy - Which drug? For which patient? For which stent? For how long?
- 'The Great Debate' - Diffuse Coronary artery disease - Available options? New strategies on the Horizon? How to best optimise the options?
- Is what you see really what you get?
- FFR assessment of coronary stenoses in series
- View more...
New features simplify delivery of contrast media in angiograms Bayer launches Medrad Mark 7 Arterion® Injection System
Tarrytown, June 20, 2012 - Bayer HealthCare’s Radiology and Interventional unit has launched the new Mark 7 Arterion® Injection System, the latest in the Medrad Mark series of angiographic injectors.
"The Arterion injection system was designed with efficiency in mind," said Diane Watson, Head of Interventional Fluid Delivery at Bayer HealthCare’s Radiology and Interventional unit. "It’s light and maneuverable with features that are meant to simplify the delivery of contrast media used in angiograms to determine the extent of arterial blockage."
The first Medrad Mark injector was introduced for use in angiograms more than 40 years ago. The Arterion injection system joins the company’s portfolio of interventional devices used to restore blood flow - providing physicians a complimentary line of products to diagnose and treat cardiovascular disease.
"The Mark 7 Arterion system's user interface facilitates the setting up and performing of contrast injections," said Robyn Reising, of Decatur Memorial Hospital where the very first Arterion system was installed in the U.S. "The front-load system shall streamline the pre- and post-procedure activities and the clear syringe allows us to monitor the purging of air."
A History of Leadership in Power Injection
The Mark 7 Arterion Injector extends more than 40 years of category leadership in providing power injectors to deliver contrast media used in angiography, computed tomography (CT) and magnetic resonance (MR) labs. In 1964, the first Medrad injector - called the Heilman-Wholey Injector - was the first flow-controlled angiographic injector commercialized in the U.S. The Arterion is the seventh in the Mark series for angiography. Operating today as Bayer HealthCare’s Radiology and Interventional business, the company remains a market leader in power injection.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at
(You will be visiting a website outside of PCRonline, we are not responsible for its contents).
Our online press service is just a click away: http://www.press.bayerhealthcare.com (You will be visiting a website outside of PCRonline, we are not responsible for its contents)
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at
(You will be visiting a website outside of PCRonline, we are not responsible for its contents). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Not intended for UK Media